The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Preliminary results from a Phase II trial on Schering-Plough's experimental Hepatitis C drug Boceprevir are promising. If the results of this study prove to be reproducible and the drug is safe, Boceprevir may help many more people defeat the Hepatitis C virus.
Continue reading »California biologists have recently discovered that a defense mechanism known to operate in other species also helps humans fight the Hepatitis C virus. MicroRNA interference explains how interferon inhibits Hepatitis C replication and will likely lead pharmaceutical companies on a new path for developing future treatments.
Continue reading »A potential Hepatitis C vaccine is beginning Phase I trials in Canada and France. Known as TG4040, this gene-based vaccine will be evaluated for safety and immune response in ribavirin/interferon non-responders and those who have yet to attempt Hepatitis C treatment.
Continue reading »Patients with Hepatitis C often experience a chronic dry mouth. Learn ten safe and valuable ways to reduce this uncomfortable symptom.
Continue reading »The lack of clotting factor in hemophiliacs' blood reduces their ability to form clots in the liver, therefore reducing their liver's ability to scar. Israeli researchers propose this to be the reason that Hepatitis C infection is less severe in hemophiliacs.
Continue reading »New research shows that people undergoing treatment for breast cancer have a greater mountain to climb when also infected with Hepatitis C. Breast cancer affects both men and women. Note: October is designated as both Breast Cancer Awareness Month and Liver Awareness Month.
Continue reading »Revealing new potential for future vaccine possibilities, University of Illinois professors have unlocked one of Hepatitis C's propagation mysteries. By using biochemical dye technology, their research demonstrates how the virus gathers enough energy to dismantle RNA and DNA to create new genetic material.
Continue reading »Pharmasset's nucleoside polymerase inhibitor, R7128, will begin a new round of testing following its positive Phase 1 results. In addition to appearing safe and well-tolerated, R7128 is showing potential to lower Hepatitis C viral load in non-responders.
Continue reading »Body Shop founder Anita Roddick died last week at the age of 64. She had announced to the media earlier this year that she had Hepatitis C, which the disease apparently had led to a previous diagnosis of liver cirrhosis. Ms. Roddick had made new inroads in social and environmental awareness and responsibility in business, while advocating for green cosmetics, animal rights, Community Trade and establishing organizations such as Children on the Edge as well as promoting the work of the Hepatitis C Trust following her diagnosis.
Continue reading »Infection with Hepatitis C genotype 3 carries a greater chance of a fatty liver than other genotypes. Although this relationship is likely due to the strain's molecular structure, successful treatment can erase this extra burden.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
